Search

Your search keyword '"Lowe, Jamie"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Lowe, Jamie" Remove constraint Author: "Lowe, Jamie"
25 results on '"Lowe, Jamie"'

Search Results

1. Solution-processed kesterite solar cells : chemistry of dissolution, thin film deposition and device fabrication

4. Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit

5. Solution-processed kesterite solar cells: chemistry of dissolution, thin film deposition and device fabrication

6. Solution processed CZTS solar cells using amine-thiol systems: understanding the dissolution process and device fabrication

8. Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

9. Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

11. Abstract LB-A31: Imprime PGG (Imprime) plus pembrolizumab (PEM): a phase 2 immunotherapeutic combination in patients selected for an Imprime-specific biomarker

12. Abstract 3688: Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites

13. A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease.

14. Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers.

15. Abstract B008: Imprime PGG, an intravenously administered beta glucan PAMP activates the innate immune system: A phase I clinical study to evaluate immunopharmacodynamic responses

16. Durability and characteristics of objective tumor responses with the innate immune cell modulator Imprime PGG in combination with standard of care frontline treatment for patients (Pts) with metastatic non-squamous NSCLC.

17. Safety of Imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two randomized phase 2 studies.

19. Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.

20. Endogenous anti-β-glucan antibodies, a potential predictive biomarker for the efficacy of soluble yeast β-1,3/1,6 glucan (Imprime PGG®) immunotherapy in cancer patients (VAC3P.947)

21. Abstract A26: Imprime PGG improves the efficacy of carboplatin, paclitaxel, and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC).

24. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

25. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Catalog

Books, media, physical & digital resources